Please assess the completion status of the following clinical trial:

Trial Title: Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Recipient Inclusion Criteria:~* 1. Understand and voluntarily sign an informed consent form.~* 2. Age 18-70 years at the time of signing the informed consent form.~* 3. Able to adhere to the study visit schedule and other protocol requirements.~* 4. Previously documented multiple myeloma (MM) with measurable monoclonal protein by either serum/urine protein electrophoresis or serum free light chains, or measurable plasmacytomas.~* 5. ECOG performance status of 0-2 at study entry (see Appendix 2).~* 6. Acceptable organ function as outlined in the protocol.~* 7. Otherwise fitting institutional criteria for allogeneic stem cell transplantation.~* 8. Presence of an HLA-matched (5/6 or 6/6 matched for HLA-A, B, and DR) sibling donor, or a HLA-matched (matched for at least HLA-A, B, C, and DRB1) unrelated donor by high-resolution testing.~* 9. Disease free of prior malignancies for \>/= 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma insitu of the cervix or breast.~* 10. All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.~* 11. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test~Recipient Exclusion Criteria:~* 1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.~* 2. Pregnant or breast feeding females.~* 3. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.~* 4. Known hypersensitivity to thalidomide or Lenalidomide.~* 5. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.~* 6. Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine or prior infection to which they are now immune (i.e., not carriers) are eligible.~Donor Inclusion Criteria:~The following categories of donor will be acceptable:~* 1. HLA-matched related donor (5/6 or 6/6 match): Minimal typing necessary is serologic typing for class I (A, B) and molecular typing for class II (DRB1).~* 2. HLA-matched Unrelated Donor (MUD): Molecular identity at least at HLA A, B, C, and DRB1 and DQB1 (8/10 match) by high resolution typing is required.~* 3. Syngeneic donors are not eligible.~* 4. The donor must be healthy and must be an acceptable donor as per institutional standards for marrow or stem cell donation.~* 5. Age ≥ 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label, Single Arm (Type: EXPERIMENTAL): Use sirolimus and tacrolimus as GvHD prophylaxis with sirolimus and lenalidomide as post-transplant maintenance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues